Myelodysplastic Syndrome (MDS) Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Omidubicel (formerly NiCord (Registered Trademark) and CordIn (TM))
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Safety Study of Cord Blood Units for Stem Cell Transplants
Recruiting
  • Aplastic Anemia
  • +3 more
  • Cord Blood Units
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
N
Biology Studies of Hematologic Cancers
Enrolling by invitation
  • Acute Lymphoblastic Leukemia
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    N
    A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
    Recruiting
    • Myelodysplastic Syndrome (MDS)
    • Houston, Texas
    • +12 more
    2022-03-29
    Mar 29, 2022
    N
    STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
    Recruiting
    • Myelodysplastic Syndrome (MDS)
    • Chandler, Arizona
    • +17 more
    2022-03-23
    Mar 23, 2022
    C
    A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
    Recruiting
    • Myelofibrosis
    • +13 more
    • Phoenix, Arizona
    • +54 more
    2022-03-04
    Mar 4, 2022
    A
    Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
    Recruiting
    • Acute Myeloid Leukemia (AML)
    • Myelodysplastic Syndrome (MDS)
    • Birmingham, Alabama
    • +36 more
    2022-03-09
    Mar 9, 2022
    A
    Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
    Recruiting
    • Myelodysplastic Syndrome (MDS)
    • Birmingham, Alabama
    • +221 more
    2022-03-08
    Mar 8, 2022
    M
    Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
    Active, not recruiting
    • Acute Myelogenous Leukemia (AML)
    • Myelodysplastic Syndrome (MDS)
    • Minneapolis, Minnesota
      Masonic Cancer Center at University of Minnesota
    2022-02-25
    Feb 25, 2022
    E
    Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
    Recruiting
    • Acute Myeloid Leukemia (AML)
    • +3 more
    • Duarte, California
    • +35 more
    2022-02-15
    Feb 15, 2022
    S
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
    Recruiting
    • Acute Lymphoblastic Leukemia (ALL)
    • +6 more
    • Anti-thymocyte globulin (rabbit)
    • +12 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    2022-01-31
    Jan 31, 2022
    G
    ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
    Recruiting
    • Acute Myeloid Leukemia (AML)
    • +2 more
    • Durham, North Carolina
      Duke University Health System
    2022-01-10
    Jan 10, 2022
    J
    Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
    Recruiting
    • Acute Myeloid Leukemia (AML)
    • +4 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    2022-01-21
    Jan 21, 2022
    H
    Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia - 2018
    Terminated
    • Myelodysplastic Syndrome (MDS)
    • Thrombocytopenia
    • Tampa, Florida
      H. Lee Moffitt Cancer Center and Research Institute
    2022-01-20
    Jan 20, 2022
    R
    Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
    Recruiting
    • Acute Myeloid Leukemia (AML)
    • +2 more
    • Reduced-Intensity Conditioning Regimen
    • Myeloablative Conditioning Regimen
    • Pittsburgh, Pennsylvania
      UPMC Children's Hospital of Pittsburgh
    2022-01-05
    Jan 5, 2022
    A
    A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes - 2020
    Completed
    • Myelodysplastic Syndrome (MDS)
    • AMV564 14-Day CIV
    • Duarte, California
    • +4 more
    2021-10-11
    Oct 11, 2021
    N
    Transplants With Unlicensed Preserved Cord Blood
    Recruiting
    • Myelodysplastic Syndrome (MDS)
    • +3 more
    • Cord Blood Transplant
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2021-09-22
    Sep 22, 2021
    B
    A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Not yet recruiting
    • Myelodysplastic Syndrome (MDS)
    • BLEX 404 Oral Liquid
    • (no location specified)
    2021-09-07
    Sep 7, 2021
    G
    Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies - 2013
    Completed
    Has Results
    • Acute Lymphoblastic Leukemia (ALL)
    • +4 more
    • Maywood, Illinois
    • +1 more
    2021-08-01
    Aug 1, 2021
    F
    A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
    Withdrawn
    • Myelodysplastic Syndrome (MDS)
    • (no location specified)
    2021-07-20
    Jul 20, 2021
    N
    Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers - 2010
    Completed
    Has Results
    • Myelodysplastic Syndrome (MDS)
    • +2 more
    • WT1:126-134
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2021-06-15
    Jun 15, 2021
    H
    Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - 2021
    Completed
    Has Results
    • Myelodysplastic Syndrome (MDS)
    • Chronic Myelomonocytic Leukemia (CMML)
    • Tampa, Florida
      H. Lee Moffitt Cancer Center and Research Institute
    2021-06-10
    Jun 10, 2021
    C
    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
    Recruiting
    • Fanconi Anemia
    • +3 more
    • New York, New York
    • +2 more
    2021-05-04
    May 4, 2021
    C
    CPX-351 Therapy for MDS After Hypomethylating Agent Failure
    Recruiting
    • Myelodysplastic Syndrome (MDS)
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
    2021-04-21
    Apr 21, 2021
    M
    A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia - 2021
    Completed
    • Fanconi Anemia
    • +2 more
    • New York, New York
    • +2 more
    2021-04-14
    Apr 14, 2021